Join the club for FREE to access the whole archive and other member benefits.

ChromaDex releases results of clinical trial demonstrating anti-inflammatory effects of NR

Gold-standard trial included 35 participants taking 1000mg of NR (or placebo) for a week


Key points from article :

ChromaDex has announced results of the 18th clinical trial on its flagship Niagen (patented nicotinamide riboside) supplement ingredient.

Adds to a growing body of clinical evidence supporting the potential anti-inflammatory effects of NR supplements.

Monocytes (a type of white blood cell that is produced in the bone marrow) had been extracted from two groups: young, healthy subjects and patients diagnosed with systemic lupus erythematosus.

SLE is an autoimmune disease in which the immune system attacks the body’s own tissues.

Results showed that increasing NAD+ levels through NR supplements reduced Type-I interferon (IFN) signalling.

“This study supplies a mechanistic foundation as to how NR blunts monocyte immunity and supports the need for future studies in patients with monocyte-driven inflammatory disease ...” - Michael Sack, study lead.

Randomised, double-blinded, placebo-controlled pilot study featured 35 healthy volunteers (average age of 24).

Participants were supplemented with 1000mg NR or placebo for 7 days.

Research published in Journal of Clinical Investigation.

Mentioned in this article:

Click on resource name for more details.


An integrated global nutraceutical company devoted to improving the way people age.

Michael Sack

Senior Investigator at NHLBI Laboratory of Mitochondrial Biology and Metabolism

The Journal of Clinical Investigation (JCI)

Monthly peer-reviewed medical journal covering biomedical research

Tru Niagen

Nicotinamide Riboside (NR) supplement from ChromaDex

Topics mentioned on this page:
NR, Inflammaging